中國生物製藥(01177.HK)與Graviton簽訂海外授權合作協議
格隆匯 2 月 24日丨中國生物製藥(01177.HK)發佈公吿, 公司附屬公司北京泰德製藥股份有限公司與美國Graviton Bioscience Corporation(“Graviton”)簽訂了海外授權合作協議,在大中華以外地區共同開發及商業化集團自主研發的治療纖維化創新藥“TDI01”。根據該協議,視乎TDI01開發和商業化的進度,集團將可收取包括按TDI01各個臨牀和註冊階段的進展情況支付的首付款和研發里程金及待TDI01上市後,於專利期內,按產品年度銷售收入的特定比例支付的許可費和銷售里程金等收益,最高可達合共5.175億美元。
TDI01是全新靶點Rho/Rho相關捲曲螺旋形成蛋白激酶2(ROCK2)的高選擇性抑制劑,國家十三五重大新藥創制品種。全新作用機制的TDI01可通過高選擇性地抑制ROCK2信號通路,發揮抑制纖維化進展、抗炎和免疫調節等多重作用,在肺纖維化、肝纖維化等領域具有較好的治療潛力。2020年,TDI01已先後獲美國食品藥品監督管理局及國家藥品監督管理局藥品評審中心批准開展臨牀試驗。目前,TDI01分別在美國和中國啟動1期臨牀試驗,進展順利。
此次集團與Graviton的戰略合作,將可充分整合雙方研發及投資團隊的優勢,進一步挖掘TDI01多種適應症的潛力,並有助於把TDI01相關產品推向全球,讓中國創新藥惠及全球更多患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.